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Structural Basis for Androgen Receptor Interdomain
and Coactivator Interactions Suggests a Transition
in Nuclear Receptor Activation Function Dominance
dependent (Metzger et al., 1992; Tremblay et al., 1999).
Activation function 2 (AF2) in the ligand binding domain
(LBD) is a highly conserved hydrophobic cleft flanked
by opposing charge residues (Webster et al., 1989; Nolte
et al., 1998; He and Wilson, 2003) that binds the LXXLL
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the N/C interaction by binding AF2 (He et al., 2002a).survival. In contrast to other nuclear receptors that
These interdomain interactions are important in regulat-bind the LXXLL motifs of coactivators, the AR ligand
ing some but not all androgen-dependent genes in tran-binding domain is preferentially engaged in an interdo-
sient reporter assays.main interaction with the AR FXXLF motif. Reported
Here we report the molecular basis for FXXLF andhere are crystal structures of the ligand-activated AR
LXXLL motif binding to AF2 based on a comparison of
ligand binding domain with and without bound FXXLF
peptide bound and peptide-free AR LBD crystal struc-
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binding specificity are identified through comparative that AR 20-30 FXXLF and TIF2-III 740-753 LXXLL motifs
structure-function and mutagenesis studies. A mecha- bind AR AF2, but only the FXXLF motif peptide binds
nism in prostate cancer is suggested by a functional with an intact primary charge clamp and better recogni-
AR mutation at a specificity-determining residue that tion conferring hydrophobic contacts than does the
recovers coactivator LXXLL motif binding. An activa- LXXLL motif. Shown are key residues that differentiate
tion function transition hypothesis is proposed in which FXXLF motif binding and a functional AR mutation in
an evolutionary decline in LXXLL motif binding paral- prostate cancer that recovers LXXLL motif binding. The
lels expansion and functional dominance of the NH2- data suggest a transition in dominant transactivation




AR FXXLF Peptide-AR LBD-R1881 Structure
Nuclear hormone receptors (NRs) are transcriptional ac- Human AR LBD bound to R1881 was cocrystallized with
tivators that regulate hormone-dependent differentia- human AR FXXLF peptide 20-30, TIF2 coactivator LXXLL
tion (Tsai and O’Malley, 1994; Chawla et al., 2001) and peptide 740-753, and without peptide. The resulting
increase gene activity by recruiting coactivators that monomeric structures contain 12  helices and 4 small
assist in chromatin remodeling (Glass and Rosenfeld,  strands assembled into the familiar 3-layer -helical
2000). Steroid receptors, a subgroup of the NR super- structure (Figures 1A and 1B). The arrangement resem-
bles structures of the progesterone receptor (PR) (Wil-family, have two predominant activation regions. Activa-
liams and Sigler, 1998), glucocorticoid receptor (GR)tion function 1 (AF1) in the NH2-terminal region is variable
(Bledsoe et al., 2002), AR (Matias et al., 2000; Sack etin sequence and its activity is receptor and cell-type
al., 2001), and other NRs (Gampe et al., 2000). R1881 is
bound in the ligand binding pocket in a mode consistent*Correspondence: emw@med.unc.edu
with that of Matias et al. (2000). The characteristic A-9Present address: M533 DeBakey Building, Department of Molecular
and D ring hydrogen (H) bonding network and other keyand Cellular Biology, Baylor College of Medicine, One Baylor Plaza,
Houston, Texas 77030. interactions are maintained.
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Figure 1. Structures of the AR FXXLF and TIF2-III LXXLL Peptides Bound to AR-R1881
(A) Global architecture of AR 20-30 FXXLF (magenta ribbon) and R1881 (space filled atoms yellow carbon and red oxygen) bound to AR LBD
(gray ribbon) with helices 3, 3, 4, and 12 (green ribbon) in AF2. Conserved charge-clamp residues are K720 (blue) in helix 3 and E897 (red)
in helix 12.
(B) Global architecture of TIF2-III 740-753 LXXLL (yellow ribbon) and R1881 (as in [A]) bound to AR LBD (orange ribbon) with helices 3, 3, 4,
and 12 (green ribbon) in AF2.
(C) A 2.0 Å C-terminal shift of bound TIF2-III (yellow ribbon) relative to bound AR FXXLF (magenta ribbon) by superimposition of (A) and (B)
(backbone root-mean-square distance [rmsd] 0.21 Å).
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Table 1. Crystallographic Data and Refinement Statistics
Crystals AR R1881 AR20-30 AR R1881 TIF2-III AR R1881 None
X-ray source Rigaku-RU-H2R-200 APS-32ID APS-17ID
Space group P212121 P212121 P212121
Unit cell a  54.9, b  66.1, c  70.4 a  54.6, b  66.7, c  69.4 a  56.9, b  65.8, c  72.6
Resolution (Å) 50.0–1.8 50.0–1.9 50.0–2.3
Unique reflections 22,123 20,036 13,364
Completeness (%) 90.4 93.0 99.4
I/ (last shell) 37.8 (2.1) 30.0 (4.7) 32.0 (2.7)
Rsyma (%) 4.1 7.3 5.7
Refinement
Resolution range 50.0–1.8 50.0–1.9 50.0–2.3
R factorb (%) 21.0 22.1 21.5
Rfree (%) 21.3 24.1 24.2
Rmsd bond lengths (Å) 0.007 0.006 0.007
Rmsd bond angles () 1.1 1.1 1.1
Total nonhydrogen atoms 2,267 2,185 2,086
Accession numbers 1XOW 1XQ2 1XQ3
Rmsd is the root-mean-square deviation from ideal geometry.
a Rsym  |Iavg  Ii|/Ii
b R factor  |FP  FPcalc|/Fp, where Fp and Fpcalc are observed and calculated structure factors; Rfree was calculated from a random set of
reflections that were excluded from refinement and R factor calculations.
Excellent quality electron density accounts for AR by L712, V716, M734, I737, M894, I898, and L26. All F23
aromatic side chain atoms lie between 3.5 and 3.9 Å ofFXXLF residues 21–30 (Figure 2A and Table 1) and is
clearly visible as a two-turn amphipathic  helix where the Q738 C	 and C
 carbons. The planar aromatic ring
of F27 contacts the C
 carbon and S	 sulfur of M734F23, L26, and F27 are directed toward the LBD surface
and Q24, N25, and Q28 are exposed to the solvent (Fig- and the K720 C	 and C carbons and is enclosed by
V716, V730, Q733, and I737. All F27 aromatic side chainure 2C). FQNLF is H bonded NH2- to C-terminal by the
conserved oxy-steroid E897 (helix 12) and K720 (helix atoms lie between 3.4 and 4.0 Å of the M734 side chain,
with additional hydrophobic contact between the L263), respectively, which reside in clusters of opposite
charge (He and Wilson, 2003). This result is reminiscent side chain and V713, V716, and M894 from helix 12.
Superimposition of backbone heavy atoms indicatesof the charge clamp originally revealed in the SRC-1-
PPAR
 (Nolte et al., 1998) and other coactivator bound no major rearrangement of the protein backbone or li-
gand binding pocket with FXXLF binding. However, con-NR structures (Darimont et al., 1998; Shiau et al., 1998;
Gampe et al., 2000). Two H bonds are observed between sistent with an induced fit mechanism, FXXLF causes
conformational changes in AR side chains contactingthe E897 carboxylate and A22 and F23 amides. Back-
bone carbonyl oxygens from F27 and V30 H bond with the peptide (Figure 1D). Charge-clamp residues K720
and E897 move and form H bonds with the peptide.the side chain of K720 (Figure 2A). No interactions are
observed from other residues that reside in either charge Side chain interactions between Q738 and F23 induce
conformational changes in V716 and in the flexiblecluster. Between the charge clusters, ten mostly hy-
drophobic residues from helices 3, 4, and 12 form the M734. An increased distance from 3.0 to 3.9 Å between
Q738 O1 and Q902 N2 suggests Q738 and F23 interac-AF2 cleft floor (I898, L712, I737, and V716, Figure 2F),
which is bounded on one side by a low rise from M894, tions disrupt a H bond network from Q738 to Q902 and
K905 in helix 12 that was observed in the peptide-freeV713, and K717, and on the other by a helix 4 ridge from
Q738, M734, V730, and Q733. Binding FXXLF increases structure. At the start of helix 4, V730 is drawn closer
to F27. Combined interactions of F27 and the FXXLFthe distance between M734 and M894 by 1.5 Å,
allowing extensive hydrophobic exposure through face C-terminal backbone force K720 toward R726, whose
guanadinium group moves 4 Å away from its locationon interactions from the F23 and F27 phenyl rings with
the helix 4 ridge of the AF2 cleft (Figures 2C and 2F). in the peptide-free structure (Figures 2C and 2F). A
change of this magnitude may be driven in part by con-Both F23 and F27 adopt similar conformers and lie in a
staggered, almost parallel orientation near M734 that tact between R726 and an adjacent molecule in the
crystal. In helix 12, M894 moves to contact L26 ofallows the planar aromatic ring of F23 to contact the
Q738 side chain (carbons C
 and C	) and be enclosed 23FQNLF27. We conclude that M734, M894, E897, and
(D) Stereoview of AR AF2 showing conformational differences in AR 20-30 bound and unbound states. Amino acid residues of AR (gray)-
R1881-FXXLF (magenta) and AR (yellow)-R1881 without peptide are superimposed (backbone rmsd 0.21 Å).
(E) Stereoview of AR AF2 showing conformational differences in TIF2-III 740-753 bound and unbound states. Amino acid residues for AR
(orange)-R1881-LXXLL (yellow) and AR (yellow)-R1881 without peptide structures are superimposed (backbone rmsd 0.20 Å).
(F) Superimposed stereoview of AR AF2 from AR FXXLF (magenta)-AR (gray)-R1881 and TIF2-III (yellow)-AR (orange)-R1881 structures
(backbone rmsd 0.21 Å). The C-terminal shifted TIF2-III fails to H bond with E897 and forces a conformational change on K720. TIF2-III L745




K720 play a prominent role in AR FXXLF binding and III peptide and undergo notable conformational change
(Figures 1E, 2D, and 2F).undergo notable conformational change along with
R726 that does not contact the peptide (Figure 1A, 2C, Superimposition of the AR structures illustrates simi-
larities and differences between the AR 20-30 and TIF2-and 2F).
III binding modes (Figures 1C, 1F, and 2E). Both amphi-
pathic peptides align along a similar helical axis andTIF2 LXXLL Peptide-AR LBD-R1881 Structure
shelter hydrophobic residues within the AF2 cleft. How-Good quality electron density defines the bound TIF2-
ever, a 2.0 Å C-terminal shift along the helical axis forIII 740–753 peptide as a two-turn amphipathic  helix
TIF2-III relative to AR20-30 is observed, separating TIF2-with L745, L748, and L749 turned toward the LBD sur-
III from charge-clamp residue AR E897 and preventingface and R746 and Y747 exposed to the solvent (Figures
H bonding. The sizeable shift and resulting absence of1B and 2D, and Table 1). Backbone amides of TIF2-III
H bonding distinguishes TIF2-III from AR 20-30 motif745LRYLL749 are too distant to H bond with the disordered
binding to the AR LBD. TIF2-III induces conformationalcarboxylate oxygen atoms of AR E897 in helix 12 or
changes where AR K720 is pushed away relative to theother residues in the negative charge cluster (Figures
FXXLF and peptide-free structures and R726 contrib-2B and 2D). Lack of an NH2-terminal backbone H bond
utes a new distant H bond to the TIF2-III L749 backboneto the charge-clamp residue distinguishes LXXLL bind-
oxygen and a closer one to the AR Q733 side chain.ing to AR from previously described coactivator bound
Despite the sizeable shift of LXXLL, the respective i1,NR structures. Disorder in the E897 carboxylate oxygens
i4, and i5 leucine residues appear in register andalso prevents defining a stable electrostatic interaction
respectively contact many of the same residues asto the proximal TIF2-III N742 N	2, which further H bonds
FXXLF. However, these contacts are fewer and less opti-to N2 of AR Q738 and participates in the H bond net-
mized due to the geometry and conformation of thework to helix 12 Q902 and K905 described above. On
branched leucine side chains in relation to the AF2the C-terminal end of LXXLL, the backbone carbonyls
surface.of L748, L749, and K751(A) accept a H bond from AR
K720 N. The side chain of AR R726 moves to strongly
Determinants of AF2 Binding SpecificityH bond (2.6 Å) with the AR Q733 side chain and weakly
Consistent with previous cell-based and in vitro binding(3.5 Å) with the TIF2-III L749 carbonyl. Ten residues in
studies (He et al., 2001; He and Wilson, 2003), the ARhelices 3, 4, and 12 interact with the branched leucine
LBD binds AR 20-30 FXXLF (9.2  0.4 M) with higherside chains in TIF2-III. Both TIF2-III L745 and L749 adopt
affinity than the LXXLL peptide TIF2-III 740-751 (78 similar conformers and lie in a staggered almost parallel
28 M) determined by fluorescence polarization (Figuresorientation near AR M734. Since fewer side chain atoms
3A and 3B). In contrast, ER LBD preferentially bindsfrom the branched TIF2-III L745 and L749 are directed
the LXXLL peptide (2.1  0.2 M) over the FXXLF pep-toward the helix 4 ridge, fewer hydrophobic contacts
tide (100 M).are made. The single C	2 methyl of L745 makes only
Crystal structures and comparative sequence align-two contacts with the AR Q738 side chain at C
 (3.3 Å)
ment (Figure 3C) suggest V730 and M734 discriminateand C	 (3.5 Å) and is enclosed by AR V716, M734, and
FXXLF and LXXLL binding. AR-V730I-M734I that mimicsM894. Likewise, TIF2-III L749 C	2 makes two contacts
PR AF2 and AR-V730L-M734V that mimics ER AF2(3.9 Å) with AR M734 C
 and S	 and is enclosed by AR
decrease binding of the AR FXXLF peptide (Figure 3D).K720, V730, and I737. Additional hydrophobic contact
The ER-like mutant also decreases binding of FXXLFoccurs between the TIF2-III L748 side chain and AR
sequences from coregulatory proteins ARA54 andM894 in helix 12 and is enclosed by AR V716 and V713.
ARA70 (Figure 3E). In contrast, both mutants increaseLike FXXLF, LXXLL peptide binding does not impose
AR binding of the TIF2-III and SRC1-IV LXXLL peptideslarge changes in the global structure, but induces con-
(Figure 3D).formational changes in AR side chains that contact or
An effect of V730 and M734 on AR FXXLF bindinglie near the peptide (Figures 1B, 1E, and 2D). Slight
was also evident in transcription assays using PSA-Enh-movement in AR E897 may arise from the adjacent TIF2-
Luc (Huang et al., 1999) and p21-Luc (Lu et al., 1999) thatIII N742 side chain since it is too distant to H bond
require the AR N/C interaction for maximal gene activation,to the peptide backbone. On the other end, AR K720
with 90% loss of activity by the AR-23FXXAA27 mutantrearranges to H bond with TIF2-III L748, L749, and the
(Figures 4A and 4B). The PR-like and ER-like AR mutantsC terminus. A movement of 2.0 Å is observed for AR
reduce androgen-dependent transactivation of these re-R726 as it forms interactions with TIF2-III L749 and AR
porters but cause little change in MMTV-Luc, a reporterQ733 (Figure 2) similar to the secondary charge clamp
less dependent on the AR N/C interaction (He et al.,described for GR (Bledsoe et al., 2002). However, 3.5 Å
2002a). The results support AR AF2 residues V730 andbetween the AR R726 side chain and TIF2-III L749 back-
M734 are critical for FXXLF motif binding.bone oxygen indicates a weak H bond, and 4.4 Å be-
tween TIF2-III R746 and AR D731 is too distant for a
second direct H bond. Thus, these interactions do not Ligand Dissociation Rates Support the Role
of M734 in FXXLF Motif Bindingqualify as a fully intact secondary charge clamp. A mod-
erate change in the flexible AR M734 side chain is seen Mutations that disrupt the AR N/C interaction exhibit
reduced half-times (t1/2) of androgen dissociation (He etas the C	2 methyls from L745 and L749 make contact
with M734. TIF2-III L745 induces a slight change in AR al., 2000, 2001). [3H]R1881 dissociation from the PR-like
mutant AR-V730I/M734I (t1/2  72  11 min; Kd  0.71 Q738 and M894 side chains. M734, Q738, M894, K720,
and in particular R726, contribute to binding the TIF2- 0.28 nM) and ER-like mutant AR-V730L/M734V (t1/2 
FXXLF and LXXLL Motif Binding Specificity to AR
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Figure 2. Structural Details for AR FXXLF and TIF2-III LXXLL Peptide-AR LBD-R1881 Complexes
(A) 2Fo  Fc electron density map (blue) contoured at 1.8 from 1.8 Å data for bound AR 20-30. Except for NH2-terminal arginine, clearly
ordered electron density is observed for all peptide residues. Carbon atoms are green, oxygen red, and nitrogen blue; annotations for AR
LBD are in yellow, AR 20-30 in orange with intact charge-clamp H bonds in solid orange lines with distances.
(B) 2Fo  Fc electron density map (blue) contoured at 1.4 from 1.9 Å data for bound TIF2-III 740-753. Electron density is devoid for K740,
D752, and D753 and poor for L744 and K751 that were built as alanine. H bond interactions are shown with solid orange lines. Excess distance
and/or the disordered E897 carboxylate oxygens prevent description of electrostatic interactions to the TIF2-III backbone amides and the
proximal N742 side chain. Also the D731 to TIF2-III R746 distance is too long to support direct H bonding (dashed yellow lines with distances
and colors as in [A]).
(C) Surface representation of AR AF2 with bound AR 20-30. AR E897, E893, and E709 with K720, K717, and R726 (Roman font) create charge
clusters (positive in blue, negative in red) that flank FQNLF (italicized font). FXXLF is charge clamped by E897 and K720.
(D) Surface representation of AR AF2 bound to TIF2-III. AR E897, E893, and E709 and K720, K717, and R726 (Roman font) create charge
clusters (positive blue, negative red) that flank LRYLL (italicized font). TIF2-III lacks backbone H bonds to AR E897 but H bonds with K720
and AR R726 that moves left to weakly H bond with L749. TIF2-III L745 and L749 make fewer less optimal hydrophobic contacts with Q738,
M734, and V730 located in AF2 (green) helix 4 ridge and K720 as does L748 to AR V713.
(E) Superimposed surface representation of the C-terminal shift of TIF2-III (yellow) to the AR FXXLF (magenta)-AR-R1881 structure (backbone
rmsd 0.21 Å). TIF2-III LRYLL i1 (not visible) and i5 leucines are shifted but in register with corresponding phenylalanines in AR 20-30.
Binding TIF2-III requires AR K720 to move (Figure 2D) allowing AR R726 to move and participate in LXXLL binding.
(F) Surface representation of peptide-free AR AF2. AR E897, E893, E709 and K720, K717, R726 present negative (red) and positive (blue)
charge clusters that flank AF2 (green).
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71  7 min; Kd  1.4  0.63 nM) was faster than from increases SRC/p160 coactivator binding (Figure 5C).
The m4 mutant in which four PR AF2 residues are re-wild-type AR (t1/2  109  11 min; Kd  0.52  0.08 nM)
(Figure 4C) even though equilibrium binding affinities placed by corresponding residues of AR, increases co-
activator binding, but to a lower extent than the singlewere not altered. A similarly fast dissociation rate from
AR-M734I (t1/2  75  7 min; Kd  0.75  0.09 nM) mutant relative to wild-type. Similarly, GAL-GR-LBD-
I572V increases coactivator interaction (Figure 5D) asindicates M734 is critical for FXXLF motif binding.
does GAL-GR-LBDm6, but to a lower extent than the
single mutant. Evolving AF2 sequence in PR and GRA Functional AR Mutation in Prostate Cancer
limits inherent transcriptional activity of AF2 by decreas-at Specificity-Determining Residue V730
ing coactivator recruitment. The decrease is less thanV730M is a functional somatic mutation that increases
that for AR where evolutionary changes favor FXXLFAR transactivation by adrenal androgens (Culig et al.,
binding.1993; Peterziel et al., 1995). Because mutations at V730
to longer side chain residues increase LXXLL motif bind-
FXXLF Motif Binding by PR and GR Mutantsing (Figure 3D, data not shown), we tested whether a
Structural determinants of AF2 binding specificity werefunctional mutation at this site alters binding specificity
tested by attempting to convert PR and GR AF2 into anand coactivator recruitment. We found the interaction
FXXLF binding site. GAL-PR-LBD and VP-AR1-660 dobetween AR-V730M and GAL-SRC1-IV increases com-
not interact, but GAL-PR-LBD-L727V interacts with thispared to wild-type AR in the presence of R1881, dihy-
AR NH2-terminal fragment (Figure 5E) and increasesdrotestosterone (DHT), androstenedione, and andro-
further when AR V713, V730, M734, and I898 replacestanediol, but not progesterone (Figures 4D and 4E).
corresponding PR residues. A similar set of mutationsThe small decrease in FXXLF binding agrees with ligand
in GAL-GR-LBD-m6 increases binding of VP-AR1-660dissociation studies that show AR-V730M (t1/2  112 
compared to wild-type GAL-GR-LBD, and binding is22 min; Kd  0.42  0.15 nM) similar to wild-type AR.
eliminated by the AR FXXAA mutation (Figure 5F). TheIn vitro binding of GST-TIF2 and GST-SRC1 LXXLL
results support M734, V730, and V713 as key residuesfragments to 35S-AR-LBD-V730M also increases in the
in AR FXXLF motif binding. It is noteworthy that PR-presence of DHT or androstenedione compared to wild-
LBDm4 and GR-LBD-m6 retain LXXLL binding (Figurestype AR (Figure 4F). But there is no increase in AR-
5C and 5D), suggesting additional determinants contrib-V730M binding of AR FXXLF in the presence of DHT.
ute to binding specificity.Specificity for FXXLF motif binding in the presence of
high-affinity androgens is also evident. The results sug-
gest somatic prostate cancer AF2 mutant AR-V730M Transition to AF1
recovers LXXLL binding with minimal effect on FXXLF Dependence of NR AF1 activity on length of the NH2-
binding. terminal domain was measured using human NR-GAL4
DNA binding domain fusion proteins expressed in
HepG2 (Figure 6A). We found an exponential increase inDeclining AF2 Activity in PR, GR, and AR
transcriptional activity with NH2-terminal domain lengthAR AF2 residue V713 is present in ER, ER, and steroid
(R  0.99, n  9), with a similar trend seen in HeLa, CV1,receptor progenitors in sea lamprey and mollusk, but is
and COS cells (data not shown). The data support thatreplaced by L727 in PR and I572 in GR (Figure 3C). In
AF1 transcriptional strength increases with NH2-terminalagreement with the structures, we found that V713 is
length as it evolves in the NR family.important for AR binding of the FXXLF and LXXLL motifs.
AR-V713L and AR-V713I mimic PR and GR at this site
and reduce binding of AR FXXLF and coactivator LXXLL Discussion
motifs (Figure 5A), suggesting selective pressure main-
tained ancestral V713 for FXXLF binding. Molecular Determinants of FXXLF
and LXXLL Motif BindingTransition of valine to longer chain residues in PR and
GR raised the possibility that LXXLL binding and AF2 Our data indicate that differential binding affinity and
specificity are established by distinct electrostatic andactivity decreases during evolution. Based on sequence
alignment and crystal structures (Williams and Sigler, hydrophobic interactions revealed in our AR-R1881
crystal structures bound with AR FXXLF and TIF2-III1998), AR AF2 V713, V730, and M734 correspond to PR
L727, I744, and I748 and GR I572, L589, and M593 (Fig- LXXLL peptides. Through an induced fit mechanism,
AR 20-30 contacts E897 with classical charge-clamp Hure 3C). Transactivation by GAL-PR-LBD-L727V is
greater than wild-type (Figure 5B) and increases with bonding that is absent in the bound TIF2-III. Although
new distant contacts form between the TIF2-III and AR,the L727V-I748V mutations that restore both ancestral
valines. GAL-GR-LBD-I572V strongly increases trans- the interactions apparently provide insufficient energy
to recover what might arise from close NH2-terminalactivation relative to wild-type, as did the corresponding
mutant GAL-GR-LBD-I572V-M593V, suggesting that backbone H bonds with E897. More importantly, selec-
tive high-affinity binding by AR AF2 of phenylalaninesevolving sequence changes in PR and GR decrease
inherent activity of AF2. Inserting a set of AR AF2 resi- at i1 and i5 suggests that the hydrophobic character,
size, and complementarity contribute a substantial non-dues in GAL-PR-LBDm4 and GAL-GR-LBDm6 reduced
AF2 activity. polar binding energy.
The crystal structures show that the AR AF2 solvent-We found that evolving sequence changes in PR and
GR that reduce AF2 activity correlate with decreased exposed hydrophobic cleft shelters hydrophobic resi-
dues of bound amphipathic peptides from the solventbinding of the SRC coactivators. GAL-PR-LBD-L727V
FXXLF and LXXLL Motif Binding Specificity to AR
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Figure 3. AF2 Determinants of FXXLF and LXXLL Motif Binding Specificity
(A and B) Affinities of FXXLF and LXXLL peptides for AR and ER LBDs. Binding of ER () and AR () LBDs to AR 20-30 ([A], FXXLF) and
TIF2-III 740-751 ([B], LXXLL) and fluoroscein-labeled peptides were measured by fluorescence polarization.
(C) Sequence alignment of AF2 surface residues for human AR GenBank M20132, human PR QRHUP, sea lamprey progestin receptor AY028458,
human GR P04150, human mineralocorticoid receptor NP000892, sea lamprey corticoid receptor AY028457, human ER P03372, human ER
NP001428, sea lamprey ER AY028456, California sea hare Aplysia californica mollusk ER AY327135, and human retinoic acid receptor 
P10276. AR AF2 residues involved in FXXLF motif binding are shaded.
(D) Substitution of PR and ER residues in AR AF2. Two-hybrid assays in HepG2 cells with and without 10 nM R1881 used 5GAL4Luc 3 and
10 ng/well pCMVhAR, AR-V730I-M734I, or AR-V730L-M734V, with 50 ng/well of GAL0, GAL-AR20-30 (ARFx), GAL-TIF2-738-756 (TIF2-III, 3rd
LXXLL), or GAL-SRC1-1428-1441 (SRC-IV, 4th and C-terminal LXXLL). Inset: schematic of two-hybrid assay for FXXLF motif binding by AR.
(E) Reduction in coregulator FXXLF motif binding by ER-like AR mutant. Two-hybrid assays in HepG2 cells with and without 10 nM R1881




Figure 4. Promoter Dependence and Prostate Cancer Functional Mutant AR-V730M
(A and B) Dependence on the AR NC interaction. Transcriptional activity of AR and mutants was determined in HepG2 cells with and without
0.1 nM R1881 using 50 ng/well pCMVhAR (WT), AR-V730I/M734I, V730L/M734V or L26A/F27A (FXXAA) with PSA-Enh-Luc, MMTV-Luc, and
p21-Luc.
(C) Reduced AR N/C interaction and increased androgen dissociation. COS cells transfected with pCMVhAR or AR-V730M, M734I, V730I-
M734I, or V730L-M734V were incubated with 10 nM [3H]R1881 and dissociation rates measured.
(D) Increase in LXXLL binding by prostate cancer AR mutant. Two-hybrid assays in HepG2 cells with and without 10 nM R1881 used 5GAL4Luc
and 10 ng/well pCMVhAR or AR-V730M with 50 ng/well GAL0, GAL-AR20-30 (GAL-ARFx), or GAL-SRC1-1428-1441 (GAL-SRC-IV).
(E) Effects of steroids on LXXLL binding. Two-hybrid assays in HeLa cells were performed with and without 10 nM DHT, androstenedione
(AD), androstanediol (OL), or progesterone (P) using 50 ng/well GAL-SRC1-IV and 10 ng/well of pCMVhAR or AR-V730M.
(F) Increase in LXXLL binding in vitro. Partially purified GST-0, GST-TIF2-624-1141 (TIF2-M), GST-SRC1-1139-1441 (SRC-C), and GST-AR4-
52 (AR-FXXLF) were incubated with 35S-AR624-919 (WT) and AR-LBD-V730M with and without 1 M DHT or androstenedione. Input lanes
have 30% of the reaction.
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Figure 5. Evolutionary Decline in AF2 Activity and FXXLF Motif Binding by PR and GR Mutants
(A) Role of AR V713. Two-hybrid assays in HepG2 cells with and without 10 nM R1881 used 5GAL4Luc3 and 5 ng/well pCMVhAR, AR-V713L,
or V713I with 50 ng/well GAL0, GAL-AR20-30 (ARFx), GAL-TIF2-738-756 (TIF2-III), or GAL-SRC1-1428-1441 (SRC-IV).
(B) Inherent transcriptional activity of PR and GR AF2 mutants. HeLa cells were assayed using 50 ng/well GAL-PR-LBD (residues 636–933)
or mutants L727V, L727V-I748V, or L727V-I744V-I748M-V912I (m4) with and without 1 nM R5020 or with 50 ng/well GAL-GR-LBD (residues
486–777) or mutants I572V, I572V-M593V, or G568E-V571L-I572V-A574V-L589V-L596I (m6) with and without 10 nM dexamethasone (DEX).
(C) Increase in LXXLL binding by PR AF2 mutants. Two-hybrid assays in HepG2 cells with or without 10 nM R5020 used 50 ng/well GAL-PR-
LBD or mutants L727V or L727V-I744V-I748M-V912I (m4) with 50 ng/well pNLVP16 (0), VP-TIF2-624-1287 (TIF2.1), VP-TRAM1-604-1297
(TRAM1.1), or VP-SRC1-568-1441 (SRC).
(D) Increase in LXXLL binding by GR AF2 mutants. Two-hybrid assays in HepG2 cells with and without 10 nM DEX used 50 ng/well GAL-GR-




Figure 6. Direct Correlation between AF1 Ac-
tivity and Length, and Models of NR Trans-
activation
(A) AF1 activity of NR NH2-terminal regions.
Human PRB1-569, AR1-503, GR1-420, ER1-
185, RXR1-134, PPAR
1-108, RAR1-87,
PXR1-40, and VDR1-23 expressed as GAL4
DNA binding domain fusion proteins (150 ng/
well) were assayed in HepG2 cells using
5GAL4Luc3.
(B) NR AF2 to AF1 transition. The data sup-
port an evolutionary transition from AF2 to
AF1 as the dominant activation function from
nonsteroid NRs to steroid receptors. Transi-
tion to AF1 parallels expansion and sequence
diversity of the NH2-terminal region. We spec-
ulate that the requirements for high-affinity
hormone binding impose structural con-
straints on AF2 that limit evolutionary diver-
sity in gene regulation. The NH2-terminal re-
gion expands in length and functional
significance during steroid receptor evolu-
tion. ER is intermediate between nonsteroid
NRs and steroid receptors.
(C) Schematic of AR gene regulation. AR
transactivation is inhibited by loss-of-func-
tion mutations that cause the androgen in-
sensitivity syndrome (AIS). AR transactivation
increases from gain-of-function mutations in
prostate cancer (PC). An AR mutant in pros-
tate cancer reverts to increased binding of
SRC/p160 coactivators LXXLL motif.
shell. The 12 aromatic phenyl carbons in FQNLF present ably position AR20-30 to H bond with E897 in helix 12.
The F23 C carbon lies 1 Å closer to I737 in the AF2a larger hydrophobic contact surface than does L745
and L749 of TIF2-III. Conformational changes to AR floor than the TIF2-III L745 C	2 methyl in the bound
745LRYLL749 structure. This orientation provides exten-M734 from F23 and F27 and M894 from L26 widens
AF2 with FXXLF compared to LXXLL. The gap distance sive and improved nonpolar contacts from F23 to Q738,
L26 to M894 and V713, and from F27 to M734 and V730between M734 and M894 sulfur atoms is 10.4 Å for
FXXLF, 8.4 Å for LXXLL, and 8.9 Å without peptide (Fig- in the helix 4 ridge.
Prominent roles of AR M734, V730, and V713 in FXXLFure 2F). The narrower gap may reflect a poorer hy-
drophobic match between TIF2-III LRYLL and AR AF2 binding and recognition are supported by ligand dissoci-
ation studies. In the PR-like mutant AR-M734I, theand may also contribute to the C-terminal shift and lost
backbone H bonds to E897. Steric hindrance from a smaller more rigid isoleucine increases ligand dissocia-
tion, suggesting important nonpolar interactions be-motif flanking residue such as L744(A) could also not
be inferred due to the absence of electron density be- tween M734 and F27 are altered. Faster ligand dissocia-
tion from the ER-like AR mutant V730L-M734V impliesyond the C carbon. For the bound 23FQNLF27, specific
enhancement of hydrophobic interactions may favor- that the larger rigid leucine and smaller rigid valine at
(E) PR AF2 mutants bind AR FXXLF. Two-hybrid assays in HepG2 cells with and without 10 nM R5020 used 50 ng/well GAL-PR-636-933 (PR-
LBD) or mutants L727V, L727V-V912I, I744V-I748M, or L727V-I744V-I748M-V912I with 50 ng/well pNLVP16 (VP-0) or VP-AR1-660.
(F) GR AF2 mutants bind AR FXXLF. Two-hybrid assays in HepG2 cells with and without 10 nM DEX used 50 ng/well GAL-GR486-777 (GR-
LBD) or mutant G568E-V571L-I572V-A574V-L589V-L596I (GR-LBDm6) with 50 ng/well VP-0, VP-AR1-660, or VP-AR1-660-FXXAA.
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F27 destabilize FQNLF interactions with AF2. Slightly nonsteroid NRs such as RXR and RAR also tend toward
NH2-terminal expansion and increased AF1 activity, al-faster ligand dissociation rates also occur for PR-like
mutant AR-V730I-M734I. Increased binding of LXXLL by though AF2 typically predominates (Nagpal et al., 1993).
ER is evolutionarily intermediate between nonsteroidthese AR mutants indicates M734 and V730 contribute
to peptide recognition. and steroid receptors (Thornton, 2001) with intermediate
NH2-terminal length and cell-type-dependent AF1 andThe contribution of V730 to FXXLF recognition is fur-
ther explained by the small valine side chain that accom- AF2 activities (Metzger et al., 1992; Tremblay et al.,
1999). Orphan NRs can also have extensive NH2-terminalmodates the bulky F27, establishing good complemen-
tary shape and distance separation. In contrast, ER, PR, regions with potent AF1 activity. AF1 of Nurr1 mediates
strong autonomous transactivation in various cellsand GR have the larger isoleucine or leucine relative to
AR V730, preferentially binding LXXLL with its smaller (Nordzell et al., 2004), whereas transactivation by its
LBD is cell-type dependent (Castro et al., 1999). Thus,i5 leucine. The even larger methionine in the AR pros-
tate cancer mutant V730M improves LXXLL binding but evolving NH2-terminal domains occur among liganded
and orphan NRs.does not greatly affect FXXLF binding. The flexible me-
thionine side chain may improve hydrophobic interac- Sequence diversity in the NH2-terminal region con-
trasts the conserved LBDs, where the structural con-tions when presented with an i5 leucine from LXXLL
or adapt to an i5 phenylalanine from FXXLF. From the straints of high-affinity hormone binding limit the binding
surfaces to LXXLL and FXXLF-like motifs. Evolution ofcrystal structures, sufficient space accommodates the
various conformations of a methionine side chain that AF1 as the dominant activation domain can provide
unique interaction sites for tissue and species-specificcould account for this exception. Mismatching FXXLF
to a receptor with larger, rigid isoleucine or leucine could coregulators. Such diversification can increase specific-
ity in gene regulation by AR, PR, GR, and the mineralo-also lead to unfavorable contacts between side chains.
Reduced interaction between FXXLF and AR V713L or corticoid receptor, which bind similar DNA response
elements. Our hypothesis for an AF2 to AF1 switch inV713I that mimic PR and GR likely result from unfavor-
able interactions between the i4 L26 and the larger dominant activation domain also allows for increased
diversity in gene regulation between receptor isoforms.mutated side chain. The data indicate AR M734, V730,
and V713 contribute to FXXLF recognition and prefer- In contrast to PR-B, PR-A is less active and can function
as a repressor through progesterone and estrogen sig-ence through optimized residue matching and comple-
mentary hydrophobic shape. naling pathways, allowing progesterone to activate and
repress gene transcription through separate isoformsOther regions of the LBD impose allosteric effects
on coactivator binding depending on the bound ligand of the same receptor. In this case, the PR LBD functions
more like a regulatory domain than a transactivation(Shulman et al., 2004; Nettles et al., 2004). AR favors
FXXLF binding when bound to DHT and LXXLL with the domain.
The hormone requirement for AR and GR DNA bindingpartial agonist androstenedione (Gregory et al., 2001).
When AR V730 and M734 are changed to corresponding may minimize inappropriate gene activity by the evolving
AF1. This contrasts nonsteroid NRs for vitamin D, thyroidresidues in PR and ER, AR binding of SRC1 and TIF2
increases in the presence of high-affinity agonists. How- hormone, and retinoic acid that have weaker AF1 activ-
ity, and in the absence of hormone, bind DNA and recruitever, transcriptional activities of the AR mutants remain
weak compared to PR or GR. Activities of PR and GR corepressors to actively repress transcription. Seques-
tering steroid receptors by heat shock proteins furtherLBDs are greater than the AR LBD when mutated at
multiple sites to mimic the AR AF2 surface, suggesting minimizes inadvertent gene activation by AF1 in the ab-
sence of hormone. For ER in the absence of hormone,additional determinants of NR AF2 activity.
AR AF2 preferentially binds FXXLF and other steroid an NH2-terminal A domain LLXXI helix competes with
the corepressor for a hydrophobic cleft in the LBD toreceptors bind LXXLL (Heery et al., 1997), but AF2 bind-
ing is not exclusive to a single motif. We show that AR maintain ER in an inactive state (Metivier et al., 2002).
binds coactivator LXXLL motifs with weaker affinity than
FXXLF but can bind artificial LXXLL peptides with higher Selective Advantage in Prostate Cancer
affinity (Chang et al., 1999). Mutated PR and GR AF2 Increased AR activity in prostate cancer is associated
bind both FXXLF and LXXLL motifs. Adaptability of AF2 with increased levels of AR (Visakorpi et al., 1995) and
is supported by variant sequences FXXLL (Huang et al., SRC/p160 coactivators, and autocrine signaling (Greg-
1998) and LXXIL (Li et al., 1999) that mediate coregula- ory et al., 2004). Functional AR mutations tend to appear
tors interactions. after antiandrogen or androgen withdrawal therapy (Gel-
mann, 2002) and contrast loss-of-function mutations
that cause androgen insensitivity (Quigley et al., 1995)Evolutionary Decline in AF2 Activity
Weak transactivation by AR AF2 (He et al., 1999) results (Figure 6C). AR transactivation is typically retained in
prostate cancer and for some mutants, transactivationfrom evolving sequence changes that reduce LXXLL
binding. Concurrently, AR FXXLF evolved with the ex- increases with different steroids (Culig et al., 1993; Pe-
terziel et al., 1995; Tan et al., 1997).panding NH2-terminal AF1 and avidly binds AF2, further
limiting coactivator recruitment by competitive binding Here we link an AR somatic prostate cancer mutation
to increased LXXLL motif binding and SRC coactivatorat AF2 (He et al., 2001) (Figure 6B). We show that evolving
sequence changes also decrease LXXLL binding by PR recruitment. AR-V730M retains high-affinity binding of
DHT and increased transcriptional activity by adrenaland GR AF2, with increasing size and functional impor-
tance of AF1 (Sartorius et al., 1994). Evolutionarily older androgens (Newmark et al., 1992; Culig et al., 1993;
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and dissociation rate studies of [3H]R1881 were determined afterPeterziel et al., 1995) (data not shown). V730M increases
transient expression in COS cells (He et al., 2001).LXXLL binding without reducing FXXLF binding and could
impact early and late stage cancer. Increased coactivator
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Accession Numbers
The Protein Data Bank (http://www.rcsb.org/pdb) accession num-
bers for the crystal structures presented here are 1XOW (FXXLF),
1XQ2 (LXXLL), and 1XQ3 (no peptide).
